Navigation Links
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
Date:7/18/2013

SOUTH SAN FRANCISCO, Calif., July 18, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases. 

Several new investors participated in the Series C financing, including the Topspin Fund, an investment group comprised of James Simons, Leo A. Guthart, Andy Gyenes and Steven Winick.  The financing also included participation from our existing investors, including The Column Group, Prospect Venture Partners, Rho Ventures and Tichenor Ventures.  With the Series C financing, NGM has raised over $130 million since the company's founding in 2008.

"With this $50 million round of equity financing, coupled with non-dilutive capital from our collaborations with Daiichi Sankyo, Janssen, MedImmune and JDRF, NGM is well-positioned to advance the promising pipeline of candidates generated by our drug discovery efforts," said William J. Rieflin, Chief Executive Officer of NGM.  "We remain focused on delivering the next generation of first-in-class therapeutics for the treatment of diabetes and other cardio-metabolic diseases."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases.  NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals, MedImmune and JDRF.  For more information, please visit the company's website at www.ngmbio.com.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
5. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
6. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
8. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
9. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... 50 years ago today, the Monterey Pop Festival opened its ... San Francisco "Summer of Love."  To celebrate the anniversary, Northern ... strategic market research portals that it will begin delivering to ... Light,s "Summer of Love (For Our Customers)."  ... Northern ...
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/13/2017)... WARSAW, Ind. , June 13, 2017 Zimmer ... in musculoskeletal healthcare, today announced that the U.S. Food and ... Letter dated June 3, 2015 relating to its ... "The successful clearance of ... China manufacturing facility is a measure of the ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), a ... new products designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric is ... care stretch twill. , With trendy looks hitting the medical community, UA Flex is ...
(Date:6/20/2017)... ... 20, 2017 , ... BrightStar Care Centerville/South Dayton, a home ... Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs in ... symbol of quality that reflects an organization’s commitment to meeting certain performance standards. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River Cruise Collection ... line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What really sets ... cruising France’s Seine River and designed small enough to dock directly in Paris. With ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water advocate ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on ... water crisis and how it affects the human eyes. , According to ...
(Date:6/20/2017)... ... June 20, 2017 , ... Bellus ... the company as Vice President of Sales, a critical role to help spearhead ... increased customer satisfaction. , Mr. McKenna is a seasoned business leader, joining Bellus ...
Breaking Medicine News(10 mins):